Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA scheduling synthetic cannabinoids 2026 update places 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA into Schedule I. These substances have high abuse potential and no accepted medical use. Clinicians should be aware of the risks…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has temporarily placed 2-fluorodeschloroketamine into Schedule I due to its abuse potential and lack of accepted medical use. This scheduling highlights regulatory challenges with novel psychoactive substances. Clinicians should be aware of…
Diphenidine Placement in Schedule I Controlled Substances
The DEA has designated diphenidine as a diphenidine schedule i controlled substance due to its high abuse potential and lack of accepted medical use. This synthetic dissociative drug is structurally related to other regulated substances and has emerged…
DEA Updates Synthetic Cannabinoid Regulation: Schedule I Placement of CUMYL-PEGACLONE
The DEA synthetic cannabinoid regulation update places CUMYL-PEGACLONE in Schedule I, reflecting its high abuse potential and no accepted medical use. This update highlights ongoing federal efforts to control emerging synthetic cannabinoids. Clinicians…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA has placed several synthetic cannabinoids into Schedule I, highlighting their high abuse potential and lack of accepted medical use. This synthetic cannabinoids schedule I classification includes 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and…